Antifungal Susceptibilities of Aspergillus fumigatus Clinical Isolates Obtained in Nagasaki, Japan by Tashiro Masato et al.
1 
 
Antifungal susceptibilities of Aspergillus fumigatus clinical isolates  
in Nagasaki, Japan  
Masato Tashiro1, Koichi Izumikawa1*, Asuka Minematsu1, Katsuji Hirano1, Naoki Iwanaga1, 
Shotaro Ide1, Tomo Mihara1, Naoki Hosogaya1, 2, Takahiro Takazono1, Yoshitomo Morinaga3, 
Shigeki Nakamura1, Shintaro Kurihara4, Yoshifumi Imamura1, Taiga Miyazaki1, Tomoya 
Nishino1, Misuzu Tsukamoto4, Hiroshi Kakeya1, Yoshihiro Yamamoto1, Katsunori Yanagihara3, 
Akira Yasuoka4, Takayoshi Tashiro5 and Shigeru Kohno1 
 
1Department of Molecular Microbiology and Immunology and 5Departments of Health Sciences, 
Nagasaki University Graduate School of Biomedical Sciences, 3Department of Laboratory 
Medicine, and 4Nagasaki University Infection Control and Education Center, Nagasaki 
University Hospital, Nagasaki, Japan.  2Department of Internal Medicine II, University of 
Yamanashi, Chuo, Japan. 
 
Running Title: Drug susceptibility of Aspergillus fumigatus in Japan 
Word count for the body text: 1344 words 
 
* Correspondence to: 
Koichi Izumikawa, M.D., Ph.D. 
Department of Molecular Microbiology and Immunology, Nagasaki University 
Graduate School of Biomedical Sciences 





Keywords. Aspergillus fumigatus, susceptibility, Japan 
2 
 
ABSTRACT (75 words) 
 
We investigated triazole, amphotericin B, and micafungin susceptibilities of 196 
A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type 
(non-WT) isolates for itraconazole, posaconazole, and voriconazole were 7.1%, 2.6%, 
and 4.1% respectively. G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) 
and 100% (5/5 isolates) of itraconazole and posaconazole non-WT isolates, 
respectively.  Amphotericin B MICs of ≥2 μg/ml and micafungin MECs of ≥16 μg/ml 
were recorded for 2 and 1 isolates, respectively. 
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The clinical importance of Aspergillus infection has increased as the number of 
immunocompromised patients has risen (16).  Recommended antifungals to treat 
patients with invasive pulmonary aspergillosis (IPA) or chronic pulmonary aspergillosis 
(CPA) are triazoles, amphotericin B, and echinocandins (13, 15, 37).  Patients with 
CPA often need years of treatment (13, 37).  Although oral therapy is important for 
carrying out long courses of treatment, azoles (with the exception of fluconazole) are 
the only class of oral drugs licensed for the treatment of aspergillosis (14, 37). 
Aspergillus fumigatus is the most common and pathogenic species of Aspergillus 
(34, 37).  Antifungal resistance of A. fumigatus especially to azoles is one of the 
concerns in treatment of aspergillosis.  During the last decade, many cases of treatment 
failure due to azole-resistance Aspergillus infection have been reported, and in the past 
few years a growing body of papers has been accumulating about antifungal 
susceptibilities of A. fumigatus (1, 3-6, 9, 10, 12, 18, 23-27, 31-33, 35, 36).  Even 
though an increased rate of azole-resistance has been reported recently in the 
Netherlands and the United Kingdom, prevalence rate of azole resistance reportedly 
remains low in other countries (1, 3, 6, 9, 12, 23, 25, 33). 
The azole target protein, lanosterol 14α-demethylase of Aspergillus is encoded 
by the cyp51A gene, and mutations of cyp51A are a major mechanism of azole 
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resistance (8, 17, 19, 20, 22, 32).  Some mutational hotspots, such as G54, M220, and 
TR/L98H, have been identified as cause of azole resistance (2, 21, 22).  Of these 
mutations, TR/L98H was especially prevalent in the Netherlands.  An environmental 
origin (resulting from agricultural antifungal drug usage) is suspected, in spite of the 
fact that the mechanism(s) of mutation induction have not been shown definitively (24, 
31, 32).   
We studied the antifungal susceptibility of 196 A. fumigatus clinical isolates 
obtained in the Pneumology Department of Nagasaki University Hospital, Nagasaki, 
Japan.  The isolates were collected between February 1994 and April 2010.  All of the 
isolates were subjected to susceptibility testing and cyp51A sequence analysis.  All 
isolates were identified as A. fumigatus by macroscopic colony morphology, 
micromorphological characteristics, and the ability to grow at 48C.  Non-wild-type 
(non-WT) isolates were subjected to additional molecular identification by 
amplification of ribosomal internal transcribed spacers (ITSs) and ribosomal 
large-subunit D1-D2 sequencing as described previously (11).  MICs of itraconazole, 
posaconazole, voriconazole, and amphotericin B and minimum effective concentrations 
(MECs) of micafungin were determined using the Clinical and Laboratory Standards 
Institute (CLSI) M38-A2 broth microdilution method.  Assays were performed using 
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RPMI 1640 broth (0.2% dextrose), final inoculum concentrations ranging from 0.4 × 
104 to 5 × 104 CFU/ml, and 48h of incubation at 35C (7).  MIC was defined as the 
lowest drug concentration that produced complete growth inhibition; MEC was read as 
the lowest concentration of drug that led to the growth of small, rounded, compact 
hyphal forms as compared to the hyphal growth seen in the growth control well.  
Susceptibility tests of non-WT isolates were performed at least three times for each 
isolate; each test was performed on different days.  Because clinical breakpoints have 
not been established yet, we adopted the use of epidemiological cutoff values (ECVs) to 
evaluate azole susceptibility (9, 25, 29).  Wild-type (WT) isolates of A. fumigatus 
(MIC ≤ ECV) were distinguished from non-WT isolates (MIC > ECV) which may 
exhibit acquired low susceptible mechanisms.  ECVs used in this study were as 
follows: itraconazole, 1 μg/ml; posaconazole, 0.5 μg/ml; voriconazole, 1 μg/ml as 
previously suggested (9, 25). 
For sequence analyses, genomic DNA was extracted from non-WT isolates using 
the MasterPure yeast DNA purification kit (Epicentre Biotechnologies, Madison, WI).  
The full coding region of the cyp51A gene was amplified as previously described (32).  
DNA sequences were determined using a BigDye Terminator version 1.1 cycle 
sequencing kit (ABI) and an ABI 3100xl DNA analyzer.  Sequence alignments were 
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performed against the sequence from an azole-susceptible strain (GenBank accession no. 
AF338659) using MacVector10.0 software (MacVector, Inc., Cary, NC) (20).  
Mutations were confirmed three times by repeating the PCR and sequencing the 
relevant region using the closest primer. 
In this study, using the ECVs, the percentages of non-WT isolates for itraconazole, 
posaconazole, and voriconazole were 7.1%, 2.6%, and 4.1% respectively (Table 1).  To 
exclude the possibility of increased proportions of non-WT isolates due to clonal spread 
(notably, the potential repeated isolation of a drug-resistant strain originating from one 
patient), we confirmed those proportions on a per-case basis, which (for non-WT 
isolates) were 7.5%, 4.3%, and 6.5% for itraconazole, posaconazole, and voriconazole, 
respectively.  These proportions of non-WT isolates were not that much different from 
other previous data from any regions, with the exception of data for the Netherlands and 
the United Kingdom (3, 9, 12, 23, 25, 33).  All the itraconazole-resistant isolates (MIC 
≥ 4μg/ml) were obtained from 1998 to 2001.  No consistent trend of increased 
proportion of non-WT isolates was observed.  Amphotericin B MICs of ≥2 μg/ml were 
recorded for 1.0% of the isolates (2/196); micafungin MECs of ≥16 μg/ml were 
recorded for 1.0% of the isolates (2/196) (Table 1).  For these antifungals, the 
proportions of resistant isolates were low and similar to those of previous reports (3, 10, 
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23, 26).   
In Japan, posaconazole has not been approved for clinical use; nonetheless, 
non-WT isolates to posaconazole already existed (Table 1).  Resistance in these 
isolates might reflect native biological variability.  Alternatively, this phenomenon 
could be associated with cross-resistance between itraconazole and posaconazole, 
because 80% (4/5) of posaconazole non-WT isolates were also itraconazole non-WT 
isolates (Table 2).  In addition, non-WT isolates of itraconazole tended to be more 
resistant to posaconazole, though not to voriconazole (Table 1).  Cross-resistance 
between itraconazole and posaconazole, but not with voriconazole, may result from the 
G54 mutation of cyp51A, which was present in 64.2% (9/14) of the itraconazole 
non-WT isolates and also present in 100% (5/5) of the posaconazole non-WT isolates 
(Table 2).  There is a known structural basis for the association of the G54 mutation 
with this pattern of cross-resistance among the azoles: unlike voriconazole, itraconazole 
and posaconazole have long side chains that clash with the amino acid side chain of the 
residue replacing G54 in the mutated CYP51A protein (8, 27, 32, 38).   
Among mutations of the cyp51A gene, TR/L98H has received the most attention, 
notably because this mutation was seen in a specific country and found in A. fumigatus 
isolated from environment (17, 22, 24, 31-33).   Recently, likewise in China, 
8 
 
TR/L98H was detected in a multi-azole resistant isolate (17), suggesting that the 
TR/L98H mutation could be selected in Asia as well as in Europe.  Of all 22 non-WT 
isolates in our study of Japanese isolates, CYP51A mutations were detected as follows: 
G54W, two isolates; G54R, one isolate; I266N, two isolates; G54E + I266N, seven 
isolates (Table 2).  No TR/L98H-bearing isolates were detected.  The I266N mutation, 
which has (to our knowledge) not been reported previously, also was seen in other 
azole-susceptible isolates; therefore, it might not be directly related to azole resistance. 
Of 21 non-WT-isolates, 9 isolates had no CYP51A substitution (Table 2).  Interestingly, 
most voriconazole non-WT isolates did not possess cyp51A mutation.  Although Bueid 
et al. reported an increase of frequency of azole-resistant isolates without cyp51A 
mutations, other possible resistant mechanisms (e.g. up-regulation of efflux pump) are 
not fully revealed yet (6, 28, 30).  Further analysis is warranted. 
Only a few previous analyses have examined changes in susceptibility over 
time; therefore, it is not clear that the frequency of azole-resistant A. fumigatus is 
increasing world-wide (12, 25, 33).  Nevertheless, mechanisms of resistance induction 
in clinical settings or the environment (e.g., selection following agricultural antifungal 
exposure) remain poorly understood.  Given that azole usage varies from one country 
to another, the mechanism of azole resistance may differ between regions. 
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In this study, we found low prevalence of resistance to triazoles in Japanese 
isolates of A. fumigatus, a clinically important fungus of increasing concern in 
respiratory medicine.  The proportions of non-WT isolates were similar to those 
previously reported for other countries.  In the future, Japanese A. fumigatus isolates 
may develop azole resistance by different mechanisms (such as TR/L98H); therefore, 
we urge the continued monitoring of azole susceptibility in this species. 
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With MIC or MECb (μg/ml):
≤0.03 0.06 0.125 0.25 0.5 1.0 2.0 4.0 8.0 ≥16
Triazoles
Itracona ole 182 (14) 1 28 107 46 (8) (4) (1) (1) 7 1z  .
Posaconazole 182 (14) 14 108 35 24 (2) (8) (1) 1 (2) (1) 2.6
Voriconazole 182 (14) 1 (3) 20 (7) 101 (2) 53 (1) 7 (1) 4.1
Polyene
Amphotericin B 182 (14) 6 8 (1) 19 (1) 90 (7) 57 (5) 2 –
Echinocandin
Micafungin 182 (14) 177 (14) 2 1 2 –
MIC di ib i f h b i d b b i f h l i l d h 14 WT i l f i la  str ut ons or eac  agent were o ta ne  y su tract ng rom t e tota  so ates teste  t e  non-  so ates o  traconazo e. 
The MIC distribution of each agent for those 14 isolates is also provided within parentheses.
b MICs are shown for amphotericin B, itraconazole, posaconazole, and voriconazole.  Minimum effective concentrations (MECs) are
shown for micafungin.
Table 1.  Tashiro et al.




MF 452 >8 0 5 0 5 I266N
 . s an  yp  su s u on o   non-  sperg us um ga us so a es 
- . .
MF-469 8 1 0.25 G54E, I266N
MF-460 4 2 0.25 G54E, I266N
MF-357 4 0.5 0.5 I266N
MF-468 4 0.5 0.25 G54E, I266N
MF-329 4 0.5 0.25 no substitution
MF-331 2 >16 0.25 G54W
MF-327 2 2 0.12 G54R
MF-439 2 0.5 0.25 G54E, I266N
MF 473 2 0 5 0 25 G54E I266N- . . , 
MF-454 2 0.5 0.12 G54E, I266N
MF-472 2 0.5 0.12 G54E, I266N
MF-843 2 0.25 2 no substitution
MF-748 2 0.25 1 NDa
MF-1011 1 2 0.12 G54W
MF-855 1 0.25 2 no substitution
MF-336 1 0.25 2 no substitution
MF-486 1 0.25 2 no substitution
MF 520 1 0 25 2 no substitution- .  
MF-1091 0.5 0.25 2 no substitution
MF-474 0.5 0.25 2 no substitution
MF-303 0.5 0.12 2 no substitution
a ND, not determined.  
Table 2.  Tashiro et al.
